🚀 VC round data is live in beta, check it out!
Avacta Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Avacta Group and similar public comparables like TaiMed Biologics, Atea Pharmaceuticals, Assembly Biosciences, Emergent BioSolutions and more.
Avacta Group Overview
About Avacta Group
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
Founded
2003
HQ
Employees
151
Website
Financials (LTM)
EV
$470M
Avacta Group Financials
Avacta Group reported last 12-month revenue of $54K and negative EBITDA of ($32M).
In the same LTM period, Avacta Group generated $54K in gross profit, ($32M) in EBITDA losses, and had net loss of ($42M).
Revenue (LTM)
Avacta Group P&L
In the most recent fiscal year, Avacta Group reported revenue of $153K and EBITDA of ($24M).
Avacta Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $54K | XXX | $153K | XXX | XXX | XXX |
| Gross Profit | $54K | XXX | $153K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | ($32M) | XXX | ($24M) | XXX | XXX | XXX |
| EBITDA Margin | (60466%) | XXX | (15596%) | XXX | XXX | XXX |
| EBIT Margin | (67522%) | XXX | (28151%) | XXX | XXX | XXX |
| Net Profit | ($42M) | XXX | ($71M) | XXX | XXX | XXX |
| Net Margin | (77461%) | XXX | (46762%) | XXX | XXX | XXX |
| Net Debt | — | — | $10M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Avacta Group Stock Performance
Avacta Group has current market cap of $460M, and enterprise value of $470M.
Market Cap Evolution
Avacta Group's stock price is $1.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $470M | $460M | 1.0% | XXX | XXX | XXX | $-0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAvacta Group Valuation Multiples
Avacta Group trades at 8766.1x EV/Revenue multiple, and (14.5x) EV/EBITDA.
EV / Revenue (LTM)
Avacta Group Financial Valuation Multiples
As of April 18, 2026, Avacta Group has market cap of $460M and EV of $470M.
Equity research analysts estimate Avacta Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Avacta Group has a P/E ratio of (11.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $460M | XXX | $460M | XXX | XXX | XXX |
| EV (current) | $470M | XXX | $470M | XXX | XXX | XXX |
| EV/Revenue | 8766.1x | XXX | 3076.2x | XXX | XXX | XXX |
| EV/EBITDA | (14.5x) | XXX | (19.7x) | XXX | XXX | XXX |
| EV/EBIT | (13.0x) | XXX | (10.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 8766.1x | XXX | 3076.2x | XXX | XXX | XXX |
| P/E | (11.1x) | XXX | (6.4x) | XXX | XXX | XXX |
| EV/FCF | (7.7x) | XXX | (14.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Avacta Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Avacta Group Margins & Growth Rates
Avacta Group's revenue in the last 12 month declined by (100%).
Avacta Group's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
Avacta Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (50%) | XXX | XXX | XXX |
| EBITDA Margin | (60466%) | XXX | (15596%) | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 10660% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 37761% | XXX | 12625% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28251% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Avacta Group Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| TaiMed Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Atea Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Assembly Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Emergent BioSolutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Altimmune | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avacta Group M&A Activity
Avacta Group acquired XXX companies to date.
Last acquisition by Avacta Group was on XXXXXXXX, XXXXX. Avacta Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Avacta Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAvacta Group Investment Activity
Avacta Group invested in XXX companies to date.
Avacta Group made its latest investment on XXXXXXXX, XXXXX. Avacta Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Avacta Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Avacta Group
| When was Avacta Group founded? | Avacta Group was founded in 2003. |
| Where is Avacta Group headquartered? | Avacta Group is headquartered in United Kingdom. |
| How many employees does Avacta Group have? | As of today, Avacta Group has over 151 employees. |
| Who is the CEO of Avacta Group? | Avacta Group's CEO is Christina Marie Coughlin. |
| Is Avacta Group publicly listed? | Yes, Avacta Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of Avacta Group? | Avacta Group trades under AVCT ticker. |
| When did Avacta Group go public? | Avacta Group went public in 2003. |
| Who are competitors of Avacta Group? | Avacta Group main competitors are TaiMed Biologics, Atea Pharmaceuticals, Assembly Biosciences, Emergent BioSolutions. |
| What is the current market cap of Avacta Group? | Avacta Group's current market cap is $460M. |
| What is the current revenue of Avacta Group? | Avacta Group's last 12 months revenue is $54K. |
| What is the current revenue growth of Avacta Group? | Avacta Group revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Avacta Group? | Current revenue multiple of Avacta Group is 8766.1x. |
| Is Avacta Group profitable? | No, Avacta Group is not profitable. |
| What is the current EBITDA of Avacta Group? | Avacta Group has negative EBITDA and is not profitable. |
| What is Avacta Group's EBITDA margin? | Avacta Group's last 12 months EBITDA margin is (60466%). |
| What is the current EV/EBITDA multiple of Avacta Group? | Current EBITDA multiple of Avacta Group is (14.5x). |
| What is the current FCF of Avacta Group? | Avacta Group's last 12 months FCF is ($61M). |
| What is Avacta Group's FCF margin? | Avacta Group's last 12 months FCF margin is (113720%). |
| What is the current EV/FCF multiple of Avacta Group? | Current FCF multiple of Avacta Group is (7.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.